1. Inhaled nitric oxide therapy decreases the risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn
- Author
-
Tanaka, Yuko, Hayashi, Tomoshige, Kitajima, Hiroyuki, Sumi, Kiyoaki, and Fujimura, Masanori
- Subjects
Nitric oxide -- Dosage and administration ,Nitric oxide -- Research ,Nitric oxide -- Complications and side effects ,Nitric oxide -- Analysis ,Cerebral palsy -- Risk factors ,Cerebral palsy -- Prevention ,Cerebral palsy -- Analysis ,Pulmonary hypertension -- Research ,Pulmonary hypertension -- Care and treatment - Abstract
OBJECTIVE. The aim was to determine whether inhaled nitric oxide therapy improves neurodevelopmental outcomes for infants with preterm persistent pulmonary hypertension of the newborn. METHODS. We conducted a historical cohort study to compare the 3-year incidence of cerebral palsy in preterm singleton infants ( RESULTS. The incidence of cerebral palsy among patients treated with inhaled nitric oxide was 12.5%, whereas that among patients treated with 100% oxygen was 46.7%. After adjustment for maternal fever ([greater than or equal to] 38[degrees]C) during delivery, birth weight, Apgar score at 5 minutes, high-frequency oscillatory ventilation, and surfactant therapy, inhaled nitric oxide therapy, compared with 100% oxygen therapy, was associated with a decreased risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn. CONCLUSION. Inhaled nitric oxide therapy decreases the risk of cerebral palsy in preterm infants with persistent pulmonary hypertension of the newborn. Key Words preterm persistent pulmonary hypertension of the newborn inhaled nitric oxide, cerebral palsy, Persistent pulmonary hypertension of the newborn (PPHN) is a disease in which the pulmonary vascular resistance remains elevated during the neonatal period. Preterm PPHN, which is associated with a high [...]
- Published
- 2007